Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
arcticnovartis
Fri, 06/12/2026 – 11:49
Read more about Novartis RemIND data at EAACI show Rhapsido® potential as first targete…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
arcticnovartis
Fri, 06/12/2026 – 11:49
Read more about Novartis RemIND data at EAACI show Rhapsido® potential as first targete…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
arcticnovartis
Fri, 06/12/2026 – 11:49
Read more about Novartis RemIND data at EAACI show Rhapsido® potential as first targete…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
arcticnovartis
Thu, 06/11/2026 – 07:04
Read more about Novartis delpacibart braxlosiran (del-brax) Phase…
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
arcticnovartis
Mon, 06/08/2026 – 09:04
Read more about Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Cong…
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
arcticnovartis
Mon, 06/08/2026 – 09:04
Read more about Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Cong…
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
arcticnovartis
Thu, 06/04/2026 – 12:19
Read more about Novartis IgAN data in The Lancet show clinically meaningful slowing…
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
arcticnovartis
Wed, 06/03/2026 – 17:34
Read more about Novartis Cosentyx® PMR data in New England Journal of Medicine sh…
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
arcticnovartis
Wed, 06/03/2026 – 17:34
Read more about Novartis Cosentyx® PMR data in New England Journal of Medicine sh…
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
arcticnovartis
Mon, 06/01/2026 – 13:19
Read more about Scemblix® continued to show superior efficacy and favorable safet…
